Table 3.
Reclassification and discrimination statistics for changes in TyG index
| C statistics | IDI | Category-free NRI | ||||
|---|---|---|---|---|---|---|
| Estimate (95% CI) | P | Estimate (95% CI), % | P | Estimate (95% CI), % | P | |
| CVD | ||||||
| Conventional modela | 0.739 (0.731–0.748) | Reference | Reference | |||
| Conventional model + changes in TyG index | 0.742 (0.733–0.751) | 0.0097 | 0.09 (0.05–0.13) | < 0.0001 | 12.58 (8.61–16.56) | < 0.0001 |
| Stroke | ||||||
| Conventional modela | 0.740 (0.730–0.750) | Reference | Reference | |||
| Conventional model + changes in TyG index | 0.742 (0.732–0.752) | 0.0435 | 0.06 (0.02–0.09) | 0.0010 | 10.83 (6.40–15.26) | < 0.0001 |
| MI | ||||||
| Conventional model* | 0.749 (0.731–0.766) | Reference | Reference | |||
| Conventional model + changes in TyG index | 0.752 (0.735–0.770) | 0.0412 | 0.03 (0.01–0.05) | 0.0365 | 16.69 (8.26–25.12) | 0.0001 |
CVD cardiovascular disease, IDI integrated discrimination improvement, MI myocardial infarction, NRI net reclassification index, TyG index triglyceride-glucose index
aConventional model was adjusted for age, sex, TyG index, education, income, smoking status, drinking status, physical activity, body mass index, systolic blood pressure, diastolic blood pressure, a history of hypertension, diabetes mellitus, and dyslipidemia, antidiabetic agents, lipid-lowering agents, antihypertensive agents, high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein at baseline